Baidu
map

2021年12月3日简报:新冠病毒奥密克戎(Omicron)变种可能是好事,或将加速终结新冠疫情,目前Omicron变种感染者均为轻症

2021-12-03 MedSci整理 MedSci整理

截至北京时间2021年12月3日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6436万例,新增636,862例,达到264,363,8

截至北京时间2021年12月3日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿6436万例,新增636,862例,达到264,363,811例。累计死亡病例524.8万例,达到5,248,441例。新增死亡为6,555例。康复为238,418,514例,重症和危重症病人达到86,955例;全球新冠确诊病例超过100万例的国家达40个,112个国家病例超10万例。昨日报道:2021年12月2日简报:美国FDA批准莫努匹拉韦用于中轻度新冠治疗,奥密克戎蔓延至全球23个国家和地区;我国还有约20%的老年人未接种新冠疫苗

全球疫苗免疫联盟:疫苗鸿沟让世界面临新冠大流行延长风险

全球疫苗免疫联盟首席执行官塞斯·伯克利1日在给新华社记者发来的一份声明中说,如果全球新冠疫苗分配不公问题不能解决,大流行将继续延长。伯克利呼吁全球共同努力,确保疫苗公平可及。

伯克利在通过电子邮件发来的声明中指出,虽然目前人类仍需更多了解奥密克戎变异毒株,“但我们知道,只要世界上大部分人没有接种疫苗,(新冠病毒)变异就会继续出现,大流行将继续延长”。

他说,只有在能够保护全球所有人口,而不仅仅是富人的情况下,才能拦阻(新冠病毒)变异。“现在全世界需共同努力,确保公平获得疫苗。”

伯克利表示,跨越疫苗鸿沟意味着疫苗制造商和捐助者为那些需要疫苗的国家提供“能见度”,以便后者实施“史上规模最大的国家免疫计划”,也意味着接受疫苗援助的国家需利用所有可用资源为需要者提供安全有效的疫苗。

“在所有人都安全之前,没有人是安全的。”伯克利强调。

由世界卫生组织、流行病防范创新联盟、全球疫苗免疫联盟共同领导的“新冠疫苗实施计划”,旨在确保所有参与的国家和经济体都能公平获得新冠疫苗。其核心目标是到2021年底提供20亿剂疫苗。

世卫组织确认:目前Omicron变种感染者均为轻症

日内瓦当地时间12月1日,在世卫组织WHO的新闻发布会上称,早期迹象表明,大多数Omicron病例的症状“轻微”。

WHO表示,虽然该变种的突变使其传播风险增加,但没有证据表明疫苗的效力有所降低。

WHO还称,即便全面旅行禁令,也无法阻止Omicron变种的传播,因此专家建议各国对旅行政策仅采取“基于证据和风险”的管控。

对此,南非总统拉马福萨也抨击认为,实施旅游禁令对阻止新冠病毒疫情扩散一无是处。

非洲南部国家博茨瓦纳卫生部一名高级官员称,在该国发现的19例Omicron感染病例中,有16例是无症状的。

然而,英国的“封城教授”Neil Ferguson却在同天警告称,可能要到月底才能更清楚地了解Omicron的风险水平。

世卫组织卫生紧急项目技术主管玛丽亚·范·科霍夫表示:现在断定奥密克戎毒株的传播率、传染性,以及是否会导致更严重的疾病还为时过早,信息仍在不断更新,研究还在进行之中。当前没有证据表明疫苗对奥密克戎毒株失去保护作用,希望人们不要恐慌。她呼吁更大范围地接种疫苗,包括普及接种加强针,可以大大降低重症和死亡病例。

英国药监局又批准一款新冠抗体疗法Xevudy

英国药监局MHRA于12月2日周四宣布,批准由葛兰素史克和Vir生物技术公司合作开发的新冠单克隆抗体疗法Xevudy (sotrovimab)上市,用于轻度至中度的高危疾病患者。

一项临床试验发现,单剂量的Sotrovimab单克隆抗体可将有症状的新冠高危成人患者的住院和死亡风险降低79%。另外,葛兰素史克表示,早期实验室测试数据表明,Sotrovimab单克隆抗体对那些携带Omicron变体的一些标志性突变的病毒有效!

英国药监局MHRA建议,Sotrovimab应该在症状出现的5天内使用,因为它已被证明在感染的早期阶段是最有效。

MHRA表示,它可以用于治疗轻或中度新冠患者,这些患者通常年纪较大,或者患有肥胖或心脏病等基础疾病。

MHRA首席执行官June Raine博士在宣布该药物获批时表示:“我很高兴地说,我们现在有了另一种安全有效的新冠治疗方法,Xevudy适用于那些有可能发展成严重疾病的人。”

世界医疗专家研判:新冠病毒Omicron变种或将加速终结新冠疫情

有专家认为,这种新的变异毒株"如果只是引起轻微的疾病,那可能会加速大流行的结束”,也就是终结这一轮疫情,甚至可能成为人类提前收到的“圣诞礼物”。

据每日邮报、英国电讯报等媒体报道,世卫组织证实,目前还没有出现感染Omicron新毒株死亡的病例。不过,世界各国的专家普遍认为,Omicron对住院率和死亡率的影响还需要两周左右时间的观察才能确定。

与世界各国表现出的恐慌情绪相反,处于震中的南非医疗专家似乎比较镇定。南非政府疫苗咨询委员会主席巴利·沙布教授(Barry Schoub)表示,南非截至目前累计共有3220个Omicron确诊病例。值得注意的是,虽然Om icron新变种似乎正在迅速传播,但住院率并没有真正上升。

沙布教授说:“目前为止发生的病例都是轻度或轻度至中度病例,这是一个好的迹象。”沙布教授强调,最重要的是,在Omicron新毒株中发现的大量突变似乎破坏了病毒的稳定性,这可能使它的适应力小于目前占主导地位的Delta 毒株。

不过他也补充说,目前对新毒株的了解还处于早期阶段,一切都尚无定论。

有专家指出,虽然Omicron因为传播得更快可能很快成为优势病毒,但结果可能是因祸得福!如果Omicron导致的普遍是轻症的话,那它挤出了更危险、更稳定的Delta毒株无疑是一件好事。南非医学协会主席安吉丽克·库切(Angelique Coetzee)对法新社表示,似乎有迹象表明,Omicron病例的症状普遍并不严重,从11月初到现在,她所接触的病人都不需住院治疗。库切表示,新变种的早期症状不同寻常,但看起来似乎相对轻微,病人一般几天内就能康复。

新加坡疫苗接种率高达93%,开放后疫情得到逐步控制

Omicron迅速在多国攀升

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
    2022-10-13 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
    2021-12-03 DR.Fu SIR

    好怀念2020年以前的世界。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
    2021-12-03 146475c0m26(暂无昵称)

    做好防护

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
    2021-12-03 冷小落

    希望疫情早日结束

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1857966, encodeId=f919185e966b9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Aug 27 05:13:52 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084661, encodeId=4d96208466144, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Oct 13 07:13:52 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076554, encodeId=532610e655474, content=好怀念2020年以前的世界。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Dec 03 13:52:15 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076467, encodeId=debe10e6467f8, content=做好防护, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Fri Dec 03 09:04:07 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076447, encodeId=207010e6447bc, content=希望疫情早日结束, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Fri Dec 03 07:25:03 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076442, encodeId=c07b10e64426b, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:20:58 CST 2021, time=2021-12-03, status=1, ipAttribution=)]
    2021-12-03 查查佳佳

    春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗

    0

相关资讯

2021年11月28日简报:新冠病毒B.1.1529变种被命名为omicron,美国、加拿大、中国香港、英国和欧盟多地发现Omicron新变种;Omicron触发金融市场大幅震荡

截至北京时间2021年11月27日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6083万例,新增549,129例,达到260,832,

FDA咨询小组支持默克公司的口服COVID-19药物,但无法确定是否对Omicron变种有效

本周二,FDA咨询小组以13票对10票的投票结果,建议默克公司的口服抗病毒药物molnupiravir紧急使用授权以治疗COVID-19。

Baidu
map
Baidu
map
Baidu
map